Collectively, these results indicate that key mechanisms of primary and acquired resistance to selective RET inhibitor therapy in RET-altered lung and thyroid cancers converge on MAPK pathway activation, with diverse yet partially overlapping and often co-existent mechanisms in individual patients. Here, RET is linked to thyroid gland carcinoma.